Sign In
Buy EYPT
$12.25
-0.610 (-4.74%)
At Close: Jul 31, 2026
Opthea's done it again: Its drug passed its DME clinical trial - Stockhead
12:16am, Wednesday, 10'th Jun 2020
Ten months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic Macular Edema (DME). This morning the company conducted a 144-patient ph
Edited Transcript of EYPT earnings conference call or presentation 6-May-20 12:30pm GMT
02:29am, Tuesday, 09'th Jun 2020
Q1 2020 EyePoint Pharmaceuticals Inc Earnings Call
COVID-19's Timing Could Not Have Been Worse For EyePoint Pharmaceuticals (NASDAQ:EYPT)
09:21am, Tuesday, 02'nd Jun 2020
Before COVID-19, EYPT's revenues were surging quarter over quarter since its Q12019 launch and consensus FY2020 and FY2021 revenue estimates were, per Seeking A
Factbox: China's numerous diplomatic disputes
12:00am, Monday, 01'st Jun 2020
Factbox: China's numerous diplomatic disputes
Should You Buy EyePoint Pharmaceuticals, Inc. (EYPT)?
04:50pm, Wednesday, 27'th May 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
EyePoint Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
11:00am, Tuesday, 26'th May 2020
WATERTOWN, Mass., May 26, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic.
Placenta Growth Factor Pipeline Review, H1 2020: Companies Involved in Therapeutics Development - ResearchAndMarkets.com
12:00am, Thursday, 21'st May 2020
The
EyePoint Pharmaceuticals, Inc. (EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of positive retrospective
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates
12:45pm, Wednesday, 06'th May 2020
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.00% and 7.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stoc
EyePoint Pharmaceuticals: Q3 Earnings Insights
12:21pm, Wednesday, 06'th May 2020
Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) were flat in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share were up 45.00% year over year to ($0.11), wh
EyePoint Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Developments
11:00am, Wednesday, 06'th May 2020
- Total revenues of $7.5 million and net product revenues of $4.7 million - - Cash conservation and reorganization initiatives coupled with recent financings.
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
12:00am, Wednesday, 06'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
Global Macular Edema Therapeutics Market 2020 Segmentation Analysis, Key Players, Industry Share and Forecast by 2025
01:29pm, Sunday, 03'rd May 2020
May 03, 2020 (CDN Newswire via Comtex) --
A recent comprehensive study titled Global Macular Edema Therapeutics Market 2020 by Company, Regions, Type and...
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
EyePoint Pharmaceuticals Announces First Quarter 2020 Financial Results Release Date and Conference Call Information
12:00pm, Wednesday, 29'th Apr 2020
WATERTOWN, Mass., April 29, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic.
